13 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
accelerated approval where a clinical trial demonstrates a relatively short-term clinical benefit in a chronic disease setting in which assessing long-term
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. ”Lupus is a complex, chronic, heterogeneous autoimmune disease impacting millions … is a chronic, inflammatory autoimmune disease driven by autoantibody-producing B cells Lupus can cause widespread organ damage, increase cardiovascular risk
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
erythematosus (SLE), the most common form of lupus. Lupus is a chronic autoimmune disease characterized by B cell dysfunction in which the immune
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
and Margarita Louis-Dreyfus professor of chronic lymphocytic leukemia and lymphoma and the director of the lymphoma program and lymphoma translational
ARS
qbiekh lfv0ljrrot
28 Apr 23
Annual report to shareholders
12:00am
10-K
hvp6fu9m
21 Mar 22
Annual report
4:19pm
424B4
w341s
23 Jul 21
Prospectus supplement with pricing info
4:24pm
S-1/A
39yhesv68
19 Jul 21
IPO registration (amended)
6:09am
S-1
wy1o kkqhrbmcmi1vtp
1 Jul 21
IPO registration
4:05pm
DRS/A
9se7w1
11 Jun 21
Draft registration statement (amended)
12:00am
DRS
zq1kql0l2vi
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next